Aclidinium Bromide Patent Expiration
Aclidinium Bromide is Used for managing symptoms of chronic obstructive pulmonary disease (COPD). It was first introduced by Covis Pharma Gmbh
Aclidinium Bromide Patents
Given below is the list of patents protecting Aclidinium Bromide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tudorza Pressair | US10034867 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul 07, 2020
(Expired) | Covis |
| Tudorza Pressair | US10085974 | Dosage and formulation | Mar 13, 2029 | Covis |
| Tudorza Pressair | US10588895 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul 07, 2020
(Expired) | Covis |
| Tudorza Pressair | US11000517 | Dosage and formulation | Mar 13, 2029 | Covis |
| Tudorza Pressair | US5840279 | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
Jun 21, 2016
(Expired) | Covis |
| Tudorza Pressair | US6071498 | Inhaler for powdered medicaments |
Jun 21, 2016
(Expired) | Covis |
| Tudorza Pressair | US6681768 | Powder formulation disintegrating system and method for dry powder inhalers |
Aug 07, 2022
(Expired) | Covis |
| Tudorza Pressair | US6750226 | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Sep 05, 2020
(Expired) | Covis |
| Tudorza Pressair | US7078412 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul 16, 2020
(Expired) | Covis |
| Tudorza Pressair | US8051851 | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler | Apr 22, 2027 | Covis |
| Tudorza Pressair | US9056100 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul 07, 2020
(Expired) | Covis |
| Tudorza Pressair | US9333195 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul 07, 2020
(Expired) | Covis |
| Tudorza Pressair | USRE46417 | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands | Feb 10, 2025 | Covis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aclidinium Bromide's patents.
Latest Legal Activities on Aclidinium Bromide's Patents
Given below is the list recent legal activities going on the following patents of Aclidinium Bromide.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| FDA Final Eligibility Letter | 07 Dec, 2015 | US6750226 |
| transaction for FDA Determination of Regulatory Review Period | 04 May, 2015 | US6750226 |
| transaction for FDA Determination of Regulatory Review Period | 19 Mar, 2015 | US6750226 |
| Correspondence Address Change | 20 Nov, 2014 | US6750226 |
| Change in Power of Attorney (May Include Associate POA) | 20 Nov, 2014 | US6750226 |
| Second letter to regulating agency to determine regulatory review period | 10 Jun, 2014 | US6750226 |
| Letter from FDA or Dept of Agriculture re PTE application | 16 Jul, 2013 | US6750226 |
| Initial letter Re: PTE Application to regulating agency | 11 Apr, 2013 | US6750226 |
| Patent Term Extension Application under 35 USC 156 Filed | 19 Sep, 2012 | US6750226 |
| Recordation of Patent Grant Mailed | 09 Aug, 2005 | US6750226 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳